Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024;101(s1):S205-S215.
doi: 10.3233/JAD-230635.

A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (REST)

Affiliations
Randomized Controlled Trial

A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (REST)

Estelle Eyob et al. J Alzheimers Dis. 2024.

Abstract

Alzheimer's disease (AD) is a leading cause of mortality and morbidity among aging populations worldwide. Despite arduous research efforts, treatment options for this devastating neurodegenerative disease are limited. Sleep disturbances, through their link to changes in neural excitability and impaired clearance of interstitial abnormal protein aggregates, are a key risk factor for the development of AD. Research also suggests that the neuroprotective effects of sleep are particularly active during slow wave sleep. Given the strong link between sleep disturbance and AD, targeting sleep in the prodromal stages of AD, such as in mild cognitive impairment (MCI), represents a promising avenue for slowing the onset of AD-related cognitive decline. In efforts to improve sleep in older individuals, several pharmacologic approaches have been employed, but many pose safety risks, concern for worsening cognitive function, and fail to effectively target slow wave sleep. Trazodone, a safe and widely used drug in the older adult population, has shown promise in inducing slow wave sleep in older adults, but requires more rigorous research to understand its effects on sleep and cognition in the prodromal stages of AD. In this review, we present the rationale and study design for our randomized, double-bind, placebo-controlled, crossover trial (NCT05282550) investigating the effects of trazodone on sleep and cognition in 100 older adults with amnestic MCI and sleep complaints.

Keywords: Alzheimer’s disease; circadian rhythms; hippocampus; mild cognitive impairment; sleep; trazodone.

PubMed Disclaimer

Conflict of interest statement

P. Rosenberg received support in the form of grant funding from the National Institute of Aging Alzheimer’s Association, Lilly, Functional Neuromodulation, Vaccinex, the Alzheimer’s Disease Cooperative Study (ADCS), Alzheimer’s Disease Trials Research Institute (ATRI), and the Alzheimer’s Clinical Trials Consortium (ACTC); he has served as a consultant to GLG, Leerink, Otsuka, Avanir, ITI, IQVIA, Food and Drug Administration, Cerevel, Bioxcel, Sunovion, and Acadia. B.

A. Spira received payment for serving as a consultant for Merck and received honoraria from Springer Nature Switzerland AG for guest editing special issues of Current Sleep Medicine Reports.

Figures

Figure 1:
Figure 1:
REST study design and visit timeline. The total study period is approximately 13–15 weeks and involves a series of five in-person visits for eligible participants. Abbreviations: Hopkins Verbal Learning Test-Revised (HVLT-R), Clinical Dementia Rating (CDR), Mini-Mental State Exam (MMSE), Neuropsychiatric Inventory-Clinician Rating Scale (NPI-C), Pittsburgh Sleep Quality Index (PSQI), Activities of Daily living (ADLs), Epworth Sleepiness Scale (ESS), Short-Form 12 Health Survey (SF-12), Home Sleep Study (HST)

References

    1. 2023 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2023;19(4):1598–1695. https://doi.org/10.1002/alz.13016. doi: 10.1002/alz.13016. - DOI - DOI - PubMed
    1. Brzecka A, Leszek J, Ashraf GM, et al. Sleep disorders associated with Alzheimer’s disease: A perspective. Frontiers in neuroscience. 2018;12:330. - PMC - PubMed
    1. Mander BA, Winer JR, Jagust WJ, Walker MP. Sleep: A novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer’s disease? Trends Neurosci. 2016;39(8):552–566. - PMC - PubMed
    1. Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer’s disease: Role of amyloid, tau, and other factors. Neuropsychopharmacology. 2020;45(1):104–120. - PMC - PubMed
    1. Xiao S, Liu Y, Lu W, et al. Possible neuropathology of sleep disturbance linking to Alzheimer’s disease: Astrocytic and microglial roles. Frontiers in Cellular Neuroscience. 2022:274. - PMC - PubMed

Publication types

LinkOut - more resources